A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 Mg Compared to Pioglitazone 45 Mg in Diabetic Dyslipidemia (PRESS V)
Journal of diabetes science and technology - United States
doi 10.1177/1932296813518680
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2014
Authors
Publisher
SAGE Publications